Next Investors logo grey

Strategic acquisition positions RotoGro in Canada's recreational cannabis market


Published 29-OCT-2018 10:42 A.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Roto-Gro International Limited (ASX:RGI) has today taken a step forward with its strategic growth plan to establish itself as a global leader in the cultivation of cannabis and perishable foods, announcing that it is in the process of acquiring Supra HC — a holder of a Health Canada issued cannabis Dealer’s Licence.

RGI entered into a definitive share purchase agreement (SPA) with Valens GroWorks Corp. (CSE:VGW) to acquire all of the issued and outstanding shares in the capital stock of Supra THC Services Inc.

The development is a major coup for RGI, with the deal giving the company cultivation, technology and agricultural services that generate revenue in their own right. Under the agreement, both RGI and VGW will collaborate on an offtake agreement for the sale and purchase of cannabis produce at the new RGI facility.

Thanks to the SPA, RGI is a unique ‘triple threat’ when compared to market peers. This is a particularly advantageous development for the company, with key analysts already flagging the potential for a huge supply gap now that cannabis is fully legal in Canada.

Both RGI and VGW will collaborate on an offtake agreement for the sale and purchase of cannabis produce at the new RGI facility.

While over 100 legal cannabis outlets have opened in Canada, a recent report by the C.D. Howe Institute projects that current suppliers will meet just 30-60% of the nationwide demand (610 tonnes).

Anindya Sen, who is an economics professor at the University of Waterloo, has made a similar claim, “There will not be enough legal supply, especially during the first half of the year following legalisation, primarily because of the slow rate of licensing producers.”

The total Canadian cannabis market will generate approximately $7.17 billion in total sales in 2019 (according to Deloitte report). Of this figure, some $4.34 billion is expected via lawful cannabis sales in the first year of legalisation alone.

With all this activity in the space, the market capitalisation of cannabis-focussed companies has increased significantly. Tilray, Canopy Growth Corp. and Aurora Cannabis Inc. have all crossed the $10 billion threshold in market capitalisation. While shares in Canopy Growth Corporation (TSX:WEED | NYSE:CGC) gained more than 30% after a C$5 billion investment by alcoholic beverage giant Constellation Brands (NYSE: STZ).

There has been some encouraging M&A activity with the following acquisitions recently completed: Aurora purchased Anandia Laboratories Inc. for C$115 million in June 2018; Nuuvera purchased ARA-Avanti Rx Analytics Inc. for $43 million in February 2018; and Wheaton purchased Dosecann LD Inc. for $38 million in April 2018.

With that in mind, RGI looks set to leverage its expanded capability at an opportune moment.

“We are very pleased with the execution of the SPA, the contemplated transaction, and becoming a shareholder of RotoGro,” Valens CEO Tyler Robson said.

“The acquisition of Supra THC is a massive step forward in the Company’s strategic growth plan to establish itself as a global leader in the cultivation of cannabis and perishable foods,” RGI Managing Director Michael Carli said.

“In addition to initiating a dialogue with Health Canada, we have identified premises where we wish to establish our cannabis operations and the design of layouts for these premises has already begun.

“We have an excellent working relationship with the management team at Valens. We look forward to our future business collaboration for offtake agreements and downstream value-added products and services,” Carli added.

About Supra THC:

Supra THC is a wholly-owned subsidiary of Valens which specialises the processing of cannabis into pure extracts and oils.

Supra THC operates pursuant to Dealer’s Licence No. 2018/6955 issued by Health Canada, and is permitted to possess cannabis and its related active ingredients.

The company has performed the following revenue-generating activities:

  • Leading-edge scientific research and development of products related to medicinal cannabis industry
  • Supply of sustained excellent product line
  • Toll processing or licences producers

Of particularly interest is Supra’s operation under accreditation using cannabis as the basis for doing so, making it the first Canadian Dealer’s License (ISO/IEC 17025) to be awarded under such terms.

The ISO 17025 accreditation has become the international standard for testing laboratories demonstrating their competency and ability to deliver reliable results.

RGI will apply for an amendment to the license to permit Standard Cultivation.

The total consideration is C$11 million paid over four instalments, with 80% to be paid in RGI shares and the remaining 20% in cash. RGI will pay 10% upon signing the SPA, with a further 10% at ownership.

The company will then pay a further 30% on award of the Processing License and the final 50% on award of the Cultivation License. Considering that RGI stock will facilitate a large proportion of payment, this is an exceptional deal for the company.

Further details regarding the transaction are available in the company’s announcement on the ASX.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.